A new study suggests that apoB testing is superior to standard LDL cholesterol tests for predicting heart risk in U.S. adults [1].

This shift in diagnostic approach matters because more accurate measurements can lead to better prevention strategies for cardiovascular events. By identifying high-risk patients who might be missed by traditional tests, clinicians can intervene earlier to reduce the incidence of heart attacks and strokes [1, 2].

Researchers found that measuring apolipoprotein B, or apoB, provides a more precise assessment of the particles that cause plaque buildup in the arteries [1]. Standard LDL measurements, while common, may not always capture the full scope of a patient's risk profile [2].

"This new research suggests that apoB testing offers superior heart risk prediction over standard LDL measurements," a researcher said [2].

The study indicates that adopting this testing method could lead to a significant decrease in cardiovascular emergencies. The findings suggest that the transition to apoB testing would remain cost-effective for the U.S. healthcare system while saving lives [1].

"Researchers found it could prevent more heart attacks and strokes while remaining cost-effective for the U.S. healthcare system," a researcher said [1].

Currently, most patients undergo standard LDL testing as part of routine blood work. However, the evidence suggests that the apoB marker is a more reliable indicator of the total number of atherogenic particles in the blood, the primary drivers of arterial blockage [1, 2].

“apoB testing offers superior heart risk prediction over standard LDL measurements”

The potential shift from LDL to apoB testing represents a move toward precision medicine in cardiology. If adopted widely, this change could refine how physicians prescribe statins and other lipid-lowering therapies, ensuring that high-risk individuals receive treatment regardless of whether their standard LDL levels appear normal.